The lab’s first pub is a nifty piece of synth bio for genome editing the brain. Richardson et al. describe a platform to test and develop new high-precision genome editing reagents. Some of our new CRISPR fusions, like eRad18-Cas9-CtIP with linear donors, showed up to 45-times higher accuracy at point-mutation editing compared to vanilla CRISPR. Another step toward direct in vivo knockin and in situ gene therapy approaches!
Congrats to Ryan and co. for “Cas9 fusions for precision in vivo editing” out on the bioRxiv!
